{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T14:06:02Z","timestamp":1792850762795,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82173125,81974374"],"award-info":[{"award-number":["82173125,81974374"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Tianjin Key Medical Discipline (Specialty) Construction Project","award":["TJYXZDXK-044A, TJYXZDXK-058B"],"award-info":[{"award-number":["TJYXZDXK-044A, TJYXZDXK-058B"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s10637-025-01558-z","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T10:00:49Z","timestamp":1753351249000},"page":"820-835","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparative analysis of engineered-exosome delivered si-HER2 and trastuzumab in the treatment of HER2-positive gastric cancer"],"prefix":"10.1007","volume":"43","author":[{"given":"Yuehong","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoyang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xipeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhansheng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"key":"1558_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492","journal-title":"CA Cancer J Clin"},{"key":"1558_CR2","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s10120-014-0402-y","volume":"18","author":"E Van Cutsem","year":"2015","unstructured":"Van Cutsem E, Bang YJ, Feng-Yi F, Xu JM, Lee KW, Jiao SC, Chong JL, Lopez-Sanchez RI, Price T, Gladkov O, Stoss O, Hill J, Ng V, Lehle M, Thomas M, Kiermaier A, Ruschoff J (2015) HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer 18:476\u2013484. https:\/\/doi.org\/10.1007\/s10120-014-0402-y","journal-title":"Gastric Cancer"},{"key":"1558_CR3","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK, To GATI (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687\u2013697. https:\/\/doi.org\/10.1016\/S0140-6736(10)61121-X","journal-title":"Lancet"},{"key":"1558_CR4","doi-asserted-by":"publisher","first-page":"753313","DOI":"10.3389\/fcvm.2021.753313","volume":"8","author":"H Xiao","year":"2021","unstructured":"Xiao H, Wang X, Li S, Liu Y, Cui Y, Deng X (2021) Advances in Biomarkers for Detecting Early Cancer Treatment-Related Cardiac Dysfunction. Front Cardiovasc Med 8:753313. https:\/\/doi.org\/10.3389\/fcvm.2021.753313","journal-title":"Front Cardiovasc Med"},{"key":"1558_CR5","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nrg3978","volume":"16","author":"A Wittrup","year":"2015","unstructured":"Wittrup A, Lieberman J (2015) Knocking down disease: a progress report on siRNA therapeutics. Nat Rev Genet 16:543\u2013552. https:\/\/doi.org\/10.1038\/nrg3978","journal-title":"Nat Rev Genet"},{"key":"1558_CR6","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1039\/c7cs00479f","volume":"47","author":"J Shen","year":"2018","unstructured":"Shen J, Zhang W, Qi R, Mao ZW, Shen H (2018) Engineering functional inorganic-organic hybrid systems: advances in siRNA therapeutics. Chem Soc Rev 47:1969\u20131995. https:\/\/doi.org\/10.1039\/c7cs00479f","journal-title":"Chem Soc Rev"},{"key":"1558_CR7","doi-asserted-by":"publisher","first-page":"4308","DOI":"10.1021\/acsami.9b21214","volume":"12","author":"Y Wang","year":"2020","unstructured":"Wang Y, Xie Y, Kilchrist KV, Li J, Duvall CL, Oupicky D (2020) Endosomolytic and Tumor-Penetrating Mesoporous Silica Nanoparticles for siRNA\/miRNA Combination Cancer Therapy. ACS Appl Mater Interfaces 12:4308\u20134322. https:\/\/doi.org\/10.1021\/acsami.9b21214","journal-title":"ACS Appl Mater Interfaces"},{"key":"1558_CR8","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3389\/fcell.2018.00018","volume":"6","author":"J Maia","year":"2018","unstructured":"Maia J, Caja S, StranoMoraes MC, Couto N, Costa-Silva B (2018) Exosome-Based Cell-Cell Communication in the Tumor Microenvironment. Front Cell Dev Biol 6:18. https:\/\/doi.org\/10.3389\/fcell.2018.00018","journal-title":"Front Cell Dev Biol"},{"key":"1558_CR9","doi-asserted-by":"publisher","unstructured":"Wang X, Zhou Y and Ding K (2021) Roles of exosomes in cancer chemotherapy resistance, progression, metastasis and immunity, and their clinical applications (Review). Int J Oncol 59. https:\/\/doi.org\/10.3892\/ijo.2021.5224","DOI":"10.3892\/ijo.2021.5224"},{"key":"1558_CR10","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/nri855","volume":"2","author":"C Thery","year":"2002","unstructured":"Thery C, Zitvogel L, Amigorena S (2002) Exosomes: composition, biogenesis and function. Nat Rev Immunol 2:569\u2013579. https:\/\/doi.org\/10.1038\/nri855","journal-title":"Nat Rev Immunol"},{"key":"1558_CR11","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1021\/acs.chemrev.7b00534","volume":"118","author":"H Shao","year":"2018","unstructured":"Shao H, Im H, Castro CM, Breakefield X, Weissleder R, Lee H (2018) New Technologies for Analysis of Extracellular Vesicles. Chem Rev 118:1917\u20131950. https:\/\/doi.org\/10.1021\/acs.chemrev.7b00534","journal-title":"Chem Rev"},{"key":"1558_CR12","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1016\/j.biomaterials.2013.11.083","volume":"35","author":"Y Tian","year":"2014","unstructured":"Tian Y, Li S, Song J, Ji T, Zhu M, Anderson GJ, Wei J, Nie G (2014) A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials 35:2383\u20132390. https:\/\/doi.org\/10.1016\/j.biomaterials.2013.11.083","journal-title":"Biomaterials"},{"key":"1558_CR13","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/j.biocel.2012.08.007","volume":"44","author":"C Bang","year":"2012","unstructured":"Bang C, Thum T (2012) Exosomes: new players in cell-cell communication. Int J Biochem Cell Biol 44:2060\u20132064. https:\/\/doi.org\/10.1016\/j.biocel.2012.08.007","journal-title":"Int J Biochem Cell Biol"},{"key":"1558_CR14","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.1002\/1878-0261.13052","volume":"15","author":"D Lin","year":"2021","unstructured":"Lin D, Zhang H, Liu R, Deng T, Ning T, Bai M, Yang Y, Zhu K, Wang J, Duan J, Ge S, Sun B, Ying G, Ba Y (2021) iRGD-modified exosomes effectively deliver CPT1A siRNA to colon cancer cells, reversing oxaliplatin resistance by regulating fatty acid oxidation. Mol Oncol 15:3430\u20133446. https:\/\/doi.org\/10.1002\/1878-0261.13052","journal-title":"Mol Oncol"},{"key":"1558_CR15","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41419-023-06220-1","volume":"14","author":"KG Zhu","year":"2023","unstructured":"Zhu KG, Yang J, Zhu Y, Zhu Q, Pan W, Deng S, He Y, Zuo D, Wang P, Han Y, Zhang HY (2023) The microprotein encoded by exosomal lncAKR1C2 promotes gastric cancer lymph node metastasis by regulating fatty acid metabolism. Cell Death Dis 14:708. https:\/\/doi.org\/10.1038\/s41419-023-06220-1","journal-title":"Cell Death Dis"},{"key":"1558_CR16","doi-asserted-by":"publisher","first-page":"e2201989","DOI":"10.1002\/adhm.202201989","volume":"12","author":"Y Yao","year":"2023","unstructured":"Yao Y, Jiang Y, Song J, Wang R, Li Z, Yang L, Wu W, Zhang L, Peng Q (2023) Exosomes as Potential Functional Nanomaterials for Tissue Engineering. Adv Healthc Mater 12:e2201989. https:\/\/doi.org\/10.1002\/adhm.202201989","journal-title":"Adv Healthc Mater"},{"key":"1558_CR17","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1126\/science.1183057","volume":"328","author":"KN Sugahara","year":"2010","unstructured":"Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Greenwald DR, Ruoslahti E (2010) Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 328:1031\u20131035. https:\/\/doi.org\/10.1126\/science.1183057","journal-title":"Science"},{"key":"1558_CR18","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1021\/acsami.1c21924","volume":"14","author":"L Sun","year":"2022","unstructured":"Sun L, Zhang J, Xu M, Zhang L, Tang Q, Chen J, Gong M, Sun S, Ge H, Wang S, Liang X, Cui L (2022) Ultrasound Microbubbles Mediated Sonosensitizer and Antibody Co-delivery for Highly Efficient Synergistic Therapy on HER2-Positive Gastric Cancer. ACS Appl Mater Interfaces 14:452\u2013463. https:\/\/doi.org\/10.1021\/acsami.1c21924","journal-title":"ACS Appl Mater Interfaces"},{"key":"1558_CR19","first-page":"15","volume":"91","author":"S Ait-Si-Ali","year":"2004","unstructured":"Ait-Si-Ali S, Guasconi V, Harel-Bellan A (2004) RNA interference and its possible use in cancer therapy. Bull Cancer 91:15\u201318","journal-title":"Bull Cancer"},{"key":"1558_CR20","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/978-1-4939-3112-5_23","volume":"1364","author":"TC Roberts","year":"2016","unstructured":"Roberts TC, Ezzat K, El Andaloussi S, Weinberg MS (2016) Synthetic SiRNA Delivery: Progress and Prospects. Methods Mol Biol 1364:291\u2013310. https:\/\/doi.org\/10.1007\/978-1-4939-3112-5_23","journal-title":"Methods Mol Biol"},{"key":"1558_CR21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1146\/annurev-pharmtox-010715-103633","volume":"56","author":"ML Bobbin","year":"2016","unstructured":"Bobbin ML, Rossi JJ (2016) RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise? Annu Rev Pharmacol Toxicol 56:103\u2013122. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010715-103633","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1558_CR22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.addr.2016.06.011","volume":"104","author":"HJ Kim","year":"2016","unstructured":"Kim HJ, Kim A, Miyata K, Kataoka K (2016) Recent progress in development of siRNA delivery vehicles for cancer therapy. Adv Drug Deliv Rev 104:61\u201377. https:\/\/doi.org\/10.1016\/j.addr.2016.06.011","journal-title":"Adv Drug Deliv Rev"},{"key":"1558_CR23","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.7150\/thno.52570","volume":"11","author":"Y Liang","year":"2021","unstructured":"Liang Y, Duan L, Lu J, Xia J (2021) Engineering exosomes for targeted drug delivery. Theranostics 11:3183\u20133195. https:\/\/doi.org\/10.7150\/thno.52570","journal-title":"Theranostics"},{"key":"1558_CR24","doi-asserted-by":"publisher","unstructured":"Kamerkar S, LeBleu VS, Sugimoto H, Yang S, Ruivo CF, Melo SA, Lee JJ, Kalluri R (2017) Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature 546:498\u2013503.\u00a0https:\/\/doi.org\/10.1038\/nature22341","DOI":"10.1038\/nature22341"},{"key":"1558_CR25","doi-asserted-by":"publisher","unstructured":"Du L, Gong Y, Zhang X, Sun J, Gao F, Shen M, Bai H, Yang T, Cheng X, Li S, Peng J, Liu Z, Ding S, Chen J, Cheng W (2024) PD-L1 siRNA hitched polyethyleneimine-elastase constituting nanovesicle induces tumor immunogenicity and PD-L1 silencing for synergistic antitumor immunotherapy. J Nanobiotechnology 22:(1)442.\u00a0https:\/\/doi.org\/10.1186\/s12951-024-02700-4","DOI":"10.1186\/s12951-024-02700-4"},{"key":"1558_CR26","doi-asserted-by":"publisher","unstructured":"Gondaliya P, Sayyed AA, Yan IK, Driscoll J, Ziemer A, Patel T (2024) Targeting PD-L1 in cholangiocarcinoma using nanovesicle-based immunotherapy. Mol Ther 32:2762\u20132777.\u00a0https:\/\/doi.org\/10.1016\/j.ymthe.2024.06.006","DOI":"10.1016\/j.ymthe.2024.06.006"},{"key":"1558_CR27","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.2147\/IJN.S362734","volume":"Volume 17","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Zhang H, Ning T, Liu D, Deng T, Liu R, Bai M, Zhu K, Li J, Fan Q, Ying G, Ba Y (2022) Exosome-Delivered c-Met siRNA Could Reverse Chemoresistance to Cisplatin in Gastric Cancer [Corrigendum]. International Journal of Nanomedicine Volume 17:1003\u20131004. https:\/\/doi.org\/10.2147\/IJN.S362734","journal-title":"International Journal of Nanomedicine"},{"key":"1558_CR28","doi-asserted-by":"publisher","unstructured":"Wang C, Li N, Li Y, Hou S, Zhang W, Meng Z, Wang S, Jia Q, Tan J, Wang R, Zhang R (2022) Engineering a HEK-293T exosome-based delivery platform for efficient tumor-targeting chemotherapy\/internal irradiation combination therapy. J Nanobiotechnology 20:247.\u00a0https:\/\/doi.org\/10.1186\/s12951-022-01462-1","DOI":"10.1186\/s12951-022-01462-1"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01558-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-025-01558-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01558-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:03:44Z","timestamp":1760195024000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-025-01558-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1558"],"URL":"https:\/\/doi.org\/10.1007\/s10637-025-01558-z","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"assertion":[{"value":"7 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"All animal studies were performed by skilled experimenters under the approval of the Ethics Committee of Tianjin Medical University Cancer Institute and Hospital and the informed consent was obtained from all patients. All experimental procedures were under an approved protocol in accordance with the principles and procedures outlined in the National Institutes of Health Guide for the Care and Use of Laboratory Animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}